New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate (ADC) for breast cancer, hoping to build on the success of a partnership that already spawned a ...

AZ and Daiichi Sankyo have also reported early-stage results for Enhertu in a small phase 2 trial looking at its potential as neoadjuvant (pre-surgery) treatment for HER-2-low early breast cancer ...

Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, today announced that its CEO and co-founder Shashi Shankar has ...

But it's not all bad news. A PET scan of a female patient with breast cancer, which has spread to the lymph nodes, bones and liver. In its recent annual report, the American Cancer Society shared ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...

A supplemental podcast curriculum improved hematology-oncology fellows’ comfort with and knowledge of medical topics, according to study results presented at ASCO Annual Meeting.The findings support ...

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...